Thanks for the link. Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%
recent technical advances using culture conditions with IL-7/IL-15 and the addition of IL-21 may enhance the enrichment for TSCM cells in the final CART product (74–76), which can be further increased with the addition of drugs blocking T-cell differentiation, such as glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products have not been developed so far. Recently, a few CART19 clinical trials for DLBCL have been conducted in which CART products were manufactured from CD62L+ isolated T cells to generate cellular products enriched for TCM cells (21, 78); however, due to prolonged culture conditions, enrichment for TSCM and TCM subsets in the infused product could not be demonstrated